Dermatology Products · LP-092
Hydrocortisone Cream
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-092Dermatology Products
- Generic identity
- HydrocortisoneCream
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-092
- Generic identity
- Hydrocortisone
- Presentation
- Cream
- Catalogue strength
- 1%; 2.5%
- Catalogue pack
- Tube 15 g / 30 g
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: hydrocortisone.
- Dosage form: cream.
- Proposed strengths: 1% and 2.5%.
- General proposed tube sizes: 15 g and 30 g.
Layer 02 · Unresolved product-specific fields
- Strength-to-tube mapping.
- Base/excipients, preservative system and dermatologic formulation characteristics.
- Approved indication, application frequency/duration, site/age restrictions and warnings.
- Storage, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 1% | Cream | — | 15/30 g tubes not mapped by strength | Final formulation and authorised topical instructions are not supplied. |
| B | 2.5% | Cream | — | 15/30 g tubes not mapped by strength | Final formulation and authorised topical instructions are not supplied. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Hydrocortisone is a corticosteroid used in appropriate skin formulations to reduce inflammation and itching in selected dermatoses. A topical cream is not equivalent to oral or injectable hydrocortisone. Strength, application site and duration affect the balance of benefit and risk. This general educational profile does not establish Luang Pharma approved indications, a cream-base specification or suitability for every rash, age group or anatomical area.
Clinical context and therapeutic role
Assessment should distinguish an inflammatory skin condition from fungal, bacterial or viral infection because steroid treatment can mask or worsen some infections. The face, skin folds, genital areas and children’s skin require particular care. The clinician considers the size of the area, severity and whether another treatment is needed. Persistent, spreading or recurrent lesions should be evaluated rather than repeatedly suppressed with a corticosteroid without a diagnosis.
Selected safety context
Skin thinning, stretch marks, color changes and worsening infection can occur, especially with inappropriate or prolonged use. Extensive application, occlusion and young age can increase systemic absorption. Use near the eyes needs specific review. A cream should not be applied to wounds or sensitive sites unless the authorized instructions permit it. Severe irritation, signs of infection or a rebound pattern after repeated use warrants assessment. The actual label determines age restrictions and maximum unsupervised use.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies a skin cream. The cream base, preservatives, excipients and suitability for particular sites require confirmation from product information. A concentration does not establish equivalence to a vaginal, oral, ophthalmic or injectable preparation containing the same ingredient. Authorized application instructions remain product-specific.
Keep the tube or container labeled, close it after use and avoid contaminating the contents. Follow the actual label for application sites, storage and expiry. Do not transfer another product’s instructions on dressings, sensitive areas or duration to this proposed presentation.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should confirm the skin diagnosis, application site, extent and suitability of the exact formulation. Unexplained, spreading or recurrent lesions need assessment. Product-specific instructions determine age restrictions, handling and permitted use.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product formulation/specification.
Approved topical label/leaflet.
Strength-to-pack SKU matrix.
Registration/market-status evidence.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Hydrocortisone for skinArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-092.
Professional enquiries
Request product-specific evidence for LP-092.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.